Regeneron (REGN) and Sanofi (SNY) announced that the European Commission has approved Dupixent for the treatment of moderate-to-severe chronic spontaneous urticaria in adult and adolescent patients 12 years and above with inadequate response to histamine-1 antihistamines and who are naive to anti-immunoglobulin E therapy for CSU. Eligible patients can use Dupixent as a first-line targeted treatment option.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN: